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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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At Therapeutics Conference, landmark study of
young gene carriers highlights how Huntington’s
disease researchers seek to solve critical puzzles
Armed with ever more impressive data and a deeper understanding of
Huntington’s disease, scientists and drug hunters convened at the 15th Annual HD
Therapeutics Conference this week, facing the complex puzzles that still hinder
the quest for treatments for this deadly neurological disorder.
One of those puzzles: how to not only treat symptoms, but to prevent them,
especially in young presymptomatic carriers of the HD gene, so that they don’t
have to spend their lives fearing the currently inevitable onset of this devastating
disease.
On February 26, Sarah Tabrizi, FRCP, Ph.D., of University College London,
answered key questions about what kinds of health consequences young
presymptomatic gene carriers suffer decades before they’re likely to develop the
disease in midlife.
Previous studies have demonstrated that brain shrinkage can occur as early as 15
to 18 years before predicted age of onset. Ranging in age from 18-40, the 64 gene
carriers in Dr. Tabrizi’s HD Young Adult Study went through state-of-the art brain
scans and cognitive testing, and also provided samples of blood and cerebrospinal
fluid (CSF) for analysis. These at-risk volunteers are, on average, 24 years from
estimated onset.
This study, in line with “The Path to Prevention” (one of five major themes of the
2020 conference), is aimed at helping identify the optimal time to treat gene
carriers to slow or prevent their neurological decline.
“Comprehensive cognitive testing was normal,” as compared to 67 non-HDaffected individuals, reported Dr. Tabrizi in her presentation to the conference.
“There were no significant psychiatric differences, which I found very interesting,
because I would have predicted they would’ve been big differences.”
Dr. Tabrizi said that "there’s always been a thought that carrying the HD gene
hard-wired you for psychiatric burden,” but the Young Adult Study suggests that
such symptoms become more prominent closer to onset.
“I think that was – and I don’t say this lightly – a landmark presentation,” Robert
Pacifici, Ph.D., the chief scientific officer for CHDI Foundation, Inc., the
conference sponsor, told me today, adding that Dr. Tabrizi’s team carried out the
study with “a high degree of rigor and granularity.”
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“The participants seem to be remarkably well,” Dr. Pacifici observed. The absence
of many of the neurological and other problems typical of HD is an encouraging
prospect for developing safe and well-tolerated treatments that could “not just
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reverse, but actually prevent” HD, he said.
Dr. Pacifici lauded the study volunteers for their "unbelievably selfless
participation," including submitting to the study's "incredibly rigorous battery."
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Above, Dr. Sarah Tabrizi presenting her talk on the HD Young Adult Study at the
2020 HD Therapeutics Conference, February 26, 2020, and, below, a closeup of
Dr. Tabrizi (photos by Gene Veritas, aka Kenneth P. Serbin)

Overall, ‘good news’ for young gene carriers
The young gene carriers in the study did appear to go through a small change in
the area of the forebrain known as the striatum, consisting primarily of the
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putamen and the caudate, the deep brain regions that are most affected by HD.
The striatum helps to control our movements and rewards system.
The study found a significant reduction in the size of the putamen, but an
insignificant reduction in the caudate. Nevertheless, Dr. Tabrizi explained that,
based on this study, these differences (in comparison with the normal subjects)
were “not associated with predicted years to onset.”
“So what we now know, based on the data, is that the striatum never appears to be
the same size as the control group,” she explained.
The “very slightly smaller” striatum may suggest a “neurodevelopmental effect”
(the way the brain develops) that is “well compensated for,” Dr. Tabrizi said,
meaning that the brain adjusts without clear damage. She added that it “might be
why the striatum is vulnerable later in life, because it has a double hit.” As
mentioned by Dr. Tabrizi, this interpretation resonates with the research of Peg
Nopoulos, M.D., who has studied the compromised development of the brains of
people affected by juvenile HD.
Alternatively, neurodegeneration early on could be “too subtle and variable” to
associate with predicated age of onset, Dr. Tabrizi noted.
Other imaging results showed no decrease in the white matter (the tissue in the
brain made of nerve fibers and possibly involved in cognitive problems in HD) or
any other aspect of the brain measured in the study, indicating that the subjects
were still “very far from onset,” Dr. Tabrizi continued.
“This is really good news,” Dr. Tabrizi stated.

Douglas Langbehn, M.D., Ph.D., a psychiatrist and biostatistician at the
University of Iowa who did the statistical analysis for the HD Young Adult Study,
listens to Dr. Tabrizi at the Therapeutics Conference (photo by Gene Veritas).
The ongoing search for reliable biomarkers
The study also involved the ongoing search for reliable biomarkers (signs of
disease and drug efficacy).
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The study detected mutant huntingtin protein in the subjects’ cerebrospinal fluid.
“CSF mutant huntingtin was higher in those closer to [predicted] onset, suggesting
that some injury is releasing mutant huntingtin [from the brain], but very subtle,”
Dr. Tabrizi said.
Several other biomarkers were elevated in the subjects’ CSF, again indicating an
early, subtle injury, but most of those subjects had readings showing levels very
close to those of the unaffected control subjects, Dr. Tabrizi continued.
Furthermore, six other biomarkers were normal, she added.
The Young Adult Study points to the one CSF biomarker in particular,
neurofilament light, a marker of brain damage, as potentially helpful in measuring
disease progression and treatment response in people decades from onset, Dr.
Tabrizi concluded.
A drug that kept neurofilament light at very low levels could prevent degeneration
of the brain, she added.
You can watch Dr. Tabrizi’s presentation in the video below.

A moving keynote address
With a record attendance of 380, the conference opened on February 24 with a
moving keynote speech by Amy Merkel, a 45-year-old nurse from Wisconsin and
the founder of Starfish Yoga.
A small company, Starfish focuses on encouraging constructive coping skills,
primarily for people affected by past imprisonment, sexual abuse, and
neurological disorders, including HD.
Amy, who titled her talk “Life is Good,” belongs to a family deeply affected by
HD. She recounted her extended family’s decades-long struggles with HD. Amy
received a standing ovation.
Stay tuned to this blog for additional reporting on the conference, including an
overview provided in my interview with Dr. Pacifici.
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Above, HD advocate Amy Merkel addresses the 15th Annual
Therapeutics Conference, and, below, poses with researchers Dr.
Sarah Tabrizi (far left), Leslie Thompson, Ph.D. (second from
right), and Gillian Bates, Ph.D. (photos by Gene Veritas).
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